An Assessment of the Effects of Coronavirus Disease 2019 (COVID-19) on Community Pharmacy Service Delivery in Lagos State
=========================================================================================================================

* Olufunke G. Ajibola
* Arinola Joda

## ABSTRACT

**Background** Community pharmacists play an important role as frontline health care workers during the COVID-19 pandemic. Therefore, the delivery of pharmaceutical care and the availability of drugs is compromised. The objective of this study was to evaluate the effect of coronavirus disease 2019 (COVID-19) on community pharmacy service delivery in Lagos state.

**Methods** A cross-sectional study with an online questionnaire created using Google Forms software was sent to community pharmacists in Lagos State, Nigeria via the Association of Community Pharmacists in Nigeria WhatsApp platforms. The sample size was 120 respondents conveniently chosen. Ethical approval was obtained from Health Research Ethics Committee, Lagos University Teaching Hospital (LUTH), Idi-Araba, Lagos State. Collected data was analyzed using Microsoft Excel.

**Results** A total of 125 respondents participated in the study. The result showed 56% were female respondents and the mean age of respondents was 32.4 ± 4.7 years. Measures such as the use of face masks (90.4%) and restricted number of patients for access at a time (89.6%) were implemented to reduce the spread of COVID-19. Majority of the respondents (61.6%) believe the measures have reduced the interaction between patients and pharmacists. Most of the respondents (81.6%) believe the pandemic has affected the availability and almost average (48%) of the respondents think that there was inflation in the prices of products like antimalarials, antibiotics, protective and preventive equipment and multivitamins.

**Conclusion** The COVID-19 pandemic has affected the delivery of pharmaceutical care to clients as well as the availability of medicines to patients. To improve the delivery of pharmaceutical care, tele-pharmacy and online pharmaceutical services may be employed.

KEYWORDS
*   Community pharmacists
*   Coronavirus disease
*   pharmaceutical care

## INTRODUCTION

The coronavirus disease 2019 (COVID-19) is a global health pandemic that has resulted in a surge in the demand for frontline healthcare personnel to meet patient care needs. It is a newly identified coronavirus that causes infectious sickness (WHO, 2020a). The virus primarily affects the respiratory system. Fever, dry cough, muscle soreness, exhaustion, anorexia and shortness of breath are the most common symptoms (Ozma et al., 2020). Droplets from the nose or mouth are the primary mechanism of transfer from person to person. According to studies, even asymptomatic patients can spread the infection (WHO, 2020b).

In Nigeria, about 206,279 cases of COVID-19 have been confirmed, with 194,167 patients discharged and 2,723 deaths confirmed as at October 4, 2021 (NCDC, 2021c). Vaccines and therapies are being developed by some scientists and the biomedical research community. Currently, short-term remedies for those that require it have centered on the use of existing antivirals (like remdesivir) that have been licensed for other illnesses off-label. Some drugs are now being tested in clinical trials to determine their efficacy and safety in the treatment of COVID-19 (Patient Safety Network, 2020). Examples of these drugs include antiviral agents like molnupiravir and favipiravir, nitazoxanide, niclosamide, immunomodulators (infliximab, abatacept and cenicriviroc) and corticosteroids (Bergman, 2021).

According to WHO (1994), community pharmacists are the most accessible health care professionals to the general populace. Community pharmacists assist patients by filling prescriptions, dispensing medications, educating and assessing patients for chronic drug renewal, providing minor illness consultations, patient monitoring and examination (WHO, 1994).

Community pharmacists are often the first point of contact with the health system for those with COVID-19-related health concerns or those who seek credible information and advice during this pandemic (Hedima et al., 2020). Community pharmacists are facing a lot of issues as a result of the pandemic in terms of ensuring patient care. These include assistance with infection prevention, supply chain management, stockpile prevention, and the dissemination of evidence-based medical information (Hayden and Parkin, 2020). Both pharmacists and patients are affected by these issues.

A previous study by Hedima et al. (2020) was concerned with the role of community pharmacies on the frontline of health service delivery against COVID-19. They ignore the important factor of how the pandemic has affected (and is still affecting) the delivery of services by the community pharmacist to patients. COVID-19 pandemic is placing extraordinary and sustained demands on the health system and providers of essential community services (Emanuel et al., 2020). The pharmacist at the frontline plays a role in providing medications and counseling to the patients, therefore community pharmacies remained open during the early active phase of pandemic and continue to stay open to attend to patients and clients.

The rapid evolution of the COVID-19 pandemic has brought about a series of changes in the community pharmacy sector. In relation to the pandemic, the Center for Disease Control (CDC) published guidelines that highlight key activities of the pharmacist in helping to curb the spread of COVID-19 (CDC, 2020b). These guidelines have caused changes to the delivery of services to patients in the pharmacy. One of such guidelines is the practice of social distancing. Pharmacists adapted their premises to achieve this measure by ensuring the use of face masks, installing barriers and floor markers to instruct waiting patients to remain six feet away from the counter or from other patients or staff. Pharmacists also restricted patient numbers for access and implemented delivery services to patients at home, especially elderly patients who have been advised to stay at home (CDC, 2020b).

Therefore, this study is aimed at assessing the effects of COVID-19 on the delivery of pharmaceutical services by community pharmacists and how pharmacists have adapted to the situation in order to satisfy customers and also curb the spread of COVID-19. The main focus includes the delivery of pharmaceutical care to patients, the availability of drugs and the price of drugs amidst the COVID-19 pandemic.

Pharmaceutical care is based on the responsible provision of drug therapy for the purpose of achieving definite outcomes which improve patient’s quality of life. Little or no study has taken into account the effects of the COVID-19 pandemic on community pharmacy services in the aspects of provision of pharmaceutical care and drug availability and prices, as these factors are crucial to both patients and pharmacists. Therefore, this study will be a useful baseline study for other researchers in this field.

The main objective of this study is to evaluate the effects of the coronavirus 2019 pandemic on community pharmacy activities.

The specific objectives are to: 

1.  Evaluate the changes caused by COVID-19 on community pharmacies with respect to delivery of pharmaceutical care and availability of medications to patients.

2.  Assess how these changes (if any) have affected the delivery of pharmaceutical care to patients.

3.  Assess how these changes have affected the availability and price of drugs in the pharmacy.

4.  Evaluate how pharmacists have adapted to these changes in order to ensure adequate provision of patient care.

This research focuses on community pharmacies in Lagos state. In light of the ongoing pandemic, the study will employ an electronic format to reach the target population.

## MATERIALS AND METHOD

### STUDY SETTING

The study was carried out in Lagos state, located in the south-western part of Nigeria. It is the most populous city in Nigeria and is the center of commercial activities in the country (Campbell, 2012). The survey was administered to registered community pharmacists via the platforms of Association of Community Pharmacists in Nigeria (ACPN) of various local government areas in Lagos state. The ACPN is the technical arm of the Pharmaceutical Society of Nigeria (PSN) committed to empowering every community pharmacist to embrace best pharmacy practice (PSN, 2019). The study was carried out between February and October, 2021.

### STUDY DESIGN

The study design used for this project was cross sectional study design.

### STUDY POPULATION

The participants involved in the study included licensed pharmacists currently working in a community pharmacy, either as the owner, superintendent pharmacist or as the pharmacist in charge.

### SAMPLE SIZE TECHNIQUES

The study involved community pharmacists with a target sample size of 120 respondents conveniently chosen.

### SAMPLING METHOD

The sampling method used in this study was convenience sampling based on the number of community pharmacists who were willing to participate in the study.

### DATA COLLECTION TOOL

The study was carried out during the pandemic; hence an online questionnaire was used. Data collection tool was created using Google Forms software, an online mobile tool which is used to design customized questionnaires. The questionnaire was structured to cover the main topics: 

1.  Sociodemographic characteristics including gender, age, position in the pharmacy and number of years in practice.

2.  Effect of COVID-19 on the delivery of pharmaceutical care.

3.  Effect of COVID-19 on drug availability and prices. A copy of the questionnaire is available in Appendix 1.

### DATA COLLECTION

The online questionnaire was administered to community pharmacists in Lagos state and their responses were the data source. The questionnaire was sent via the ACPN online platforms as well as other available community pharmacists’ WhatsApp group chats to allow willing pharmacists to participate in the study. The survey was sent out between June and August, 2021, during which daily reminders were sent to get as many responses as possible.

### DATA ANALYSIS

Data collected was pre-analyzed using the Google Forms software and was further subjected to descriptive statistical analysis using Microsoft Excel software. Descriptive data were presented in tables, bar charts and pie chart. Frequencies and percentages were also used for analysis of data. Comparisons across demographic characteristics were made using Chi square statistics. A probability of 0.05 or less was considered to be significant. For qualitative questions, thematic analysis of responses was performed using appropriate codes.

### ETHICAL CONSIDERATIONS

For this study, ethical approval was obtained from the Health Research Ethics Committee, Lagos University Teaching Hospital (LUTH), Idi-Araba, Lagos, Nigeria, by a Notice of Exemption. The Health Research Committee assigned number was ADM/DCST/HREC/APP/4167. The pharmacists who participated in filling the questionnaires gave their consent. Utmost confidentiality was ensured during and after data collection.

## RESULTS

Consequently, the questionnaires were distributed to one hundred and fifty (150) community pharmacists and one hundred and twenty-five (125) responses were retrieved. The response rate was 83.33%.

### SOCIODEMOGRAPHIC CHARACTERISTICS

Table 1 shows that from a total of 125 respondents, more than half (56%) were female, and with majority falling within the age range of 25-34 years with the mean age of 32.4 ± 4.7 years. Most of the community pharmacist respondents (67.2%) have been practicing for 0-5 years.

View this table:
[Table 1.](http://medrxiv.org/content/early/2024/11/17/2024.11.02.24316307/T1)

Table 1. Sociodemographic characteristics of respondents

Figure 1 below shows that majority of the respondents were locum pharmacists (34%), while 16.8% of the respondents were full time pharmacists.

![Figure 1.](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2024/11/17/2024.11.02.24316307/F1.medium.gif)

[Figure 1.](http://medrxiv.org/content/early/2024/11/17/2024.11.02.24316307/F1)

Figure 1. Status of respondents

### EFFECT OF COVID-19 ON DELIVERY OF PHARMACEUTICAL CARE

The table below shows that the majority of the participants (56%) think there was a total lockdown in the state. Community pharmacies operated during the initial active phase of the pandemic and many (96.8%) of the respondents’ community pharmacies operated during the initial active phase of the pandemic.

View this table:
[Table 2.](http://medrxiv.org/content/early/2024/11/17/2024.11.02.24316307/T2)

Table 2. Community pharmacy operation during the lockdown

Table 3 below shows that most participants practiced the recommended measures to help curb the spread of coronavirus. The most implemented measure was the use of face masks (90.4%). Other commonly practiced measures included restriction in the number of patients for access at a time (90.4%), reduction in number of staff on duty (76.8%) and advice for elderly patients to stay at home (74.4%). Chi square testing against gender and pharmacy status identified that no statistically significant difference exists when compared to the variables.

View this table:
[Table 3.](http://medrxiv.org/content/early/2024/11/17/2024.11.02.24316307/T3)

Table 3. Measures adopted during COVID-19

Table 4 below shows that the measures adopted during the initial active phase of COVID-19 are still being utilized by some pharmacies and many respondents (68.8%) believe the measures against COVID-19 have affected delivery of pharmaceutical care to patients.

View this table:
[Table 4.](http://medrxiv.org/content/early/2024/11/17/2024.11.02.24316307/T4)

Table 4. Utilization and effects of measures adopted during the initial active phase of the pandemic

Figure 2 below shows how the measures implemented have affected the delivery of pharmaceutical care to patients. The top three include decreased time spent with patients during counselling (61.6%), pharmacists no longer checking blood pressure and blood sugar level (40%) increased sales of point of care testing devices (38.4%).

![Figure 2.](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2024/11/17/2024.11.02.24316307/F2.medium.gif)

[Figure 2.](http://medrxiv.org/content/early/2024/11/17/2024.11.02.24316307/F2)

Figure 2. 
Effect of COVID-19 on the delivery of pharmaceutical care

Table 5 shows that less than half (45.6%) of the respondents believe that the virus has caused moderately positive effects on the pharmaceutical care delivery, while a few of the respondents (32%) believe that there have been moderately negative effects.

View this table:
[Table 5.](http://medrxiv.org/content/early/2024/11/17/2024.11.02.24316307/T5)

Table 5. Rate of effect of measures adopted during the pandemic on the patients care delivery.

Table 6 shows how respondents have adapted to the changes to ensure delivery of pharmaceutical care. Four thematic areas emerged from respondents on how they ensured the delivery of pharmaceutical care during the pandemic. Many of the respondents ensured the adaptation of the COVID-19 protocols.

View this table:
[Table 6.](http://medrxiv.org/content/early/2024/11/17/2024.11.02.24316307/T6)

Table 6. How respondents ensured the delivery of pharmaceutical care during the pandemic

### FFECT OF COVID-19 ON DRUG AVAILABILITY AND PRICES

Figure 3 below shows that the COVID-19 has affected the ready availability of medicines in the majority of the respondents’ pharmacies (81.6%).

![Figure 3.](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2024/11/17/2024.11.02.24316307/F3.medium.gif)

[Figure 3.](http://medrxiv.org/content/early/2024/11/17/2024.11.02.24316307/F3)

Figure 3. 
Effect of COVID-19 on the ready availability of medicines in the pharmacy

Table 7 shows that the most affected class of pharmaceutical products was COVID-19 pharmaceutical goods (53.6%). Others were antimalarials (16.8%), antimicrobials (14.4%) and multivitamins (4.7%).

View this table:
[Table 7.](http://medrxiv.org/content/early/2024/11/17/2024.11.02.24316307/T7)

Table 7. Classes of medicines most affected

The medicines that were in short supply in most of the respondents’ pharmacies include antibiotics (24.8%), immune boosters (18.4%) and hydroxychloroquine (12%).

View this table:
[Table 8.](http://medrxiv.org/content/early/2024/11/17/2024.11.02.24316307/T8)

Table 8. Medicines Short in Supply

Figure 4 shows that some of the respondents (48%) believe that there were dramatic price changes on a few medicines.

![Figure 4.](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2024/11/17/2024.11.02.24316307/F4.medium.gif)

[Figure 4.](http://medrxiv.org/content/early/2024/11/17/2024.11.02.24316307/F4)

Figure 4. 
Rating of price changes

Table 9 shows that multivitamins and immune boosters had the most dramatic price changes (28.7%). Other medications with dramatic price changes were antimalarials, antibiotics and ivermectin.

View this table:
[Table 9.](http://medrxiv.org/content/early/2024/11/17/2024.11.02.24316307/T9)

Table 9. Medicines with dramatic price changes

From Table 10 below, the majority of the respondents (18.4%) were constantly able to contact distributors for supply of drugs during the initial active phase of the pandemic.

View this table:
[Table 10.](http://medrxiv.org/content/early/2024/11/17/2024.11.02.24316307/T10)

Table 10. Ways by which respondents were able to meet patients’ drug supply needs during the initial active phase of the pandemic

## DISCUSSION

This study was carried out with the aim of assessing the effect of COVID-19 on community pharmacy service delivery. Of 125 participants, 56% were female. This is similar to a study in the Netherlands which had 64.7% female participants (Koster et al., 2020b). The modal age range was 25-34 years with a mean age of 32.4 ± 4.7 years. This was in contrast with the study in the Netherlands which had a mean age of 43.4 ± 11.5 years (Koster et al., 2020b). A great percentage of the respondents were locum pharmacists and only few of the respondents were pharmacy owners. This is in contrast to a study carried out in Australia where the majority of the participants were full-time pharmacists and only a few were locum pharmacists (Sum and Ow, 2020). This could be due to the use of online platforms containing more locum pharmacists and less pharmacy owners. Majority of the respondents have had 0-5 years of practice. This is similar to a study carried out in Switzerland in which 79% of the respondents have had <5 years of experience as community pharmacists (Hoti et al., 2020).

The lockdown in Lagos state took effect on March 30, 2020 (Mbah, 2020). Majority of the respondents’ community pharmacies were actively operating during this period. This shows that during the pandemic, community pharmacists were the first point of contact for individuals and they remained accessible to patients, providing health related information and advice (Sum and Ow, 2020).

Actions in response to coronavirus were mainly aimed at reducing direct patient contact and limiting the number of patients visiting the pharmacy. The findings show that the measures implemented by the NCDC and CDC were implemented in most community pharmacies. However, there was a variability in the frequency of uptake of some of these measures. For example, the use of face masks, restriction of the number of patients for access at a time, reduction in number of staff on duty and advice for elderly patients to stay at home were implemented by the majority of the pharmacies. The use of glass barriers, however, was less frequently implemented. The study carried out in the Netherlands showed that community pharmacists suggested the use of plastic or glass barriers as a standard for hygiene in the pharmacy (Koster et al., 2020b). Majority of the community pharmacists ensured the use of face masks in the pharmacy. The use of face masks has been proved to be effective in reducing transmission of the coronavirus (Esposito et al., 2020). More than half of the respondents indicated that the measures are still in use.

The study also reveals that more than half of the pharmacists believed the pandemic has affected the delivery of pharmaceutical care to patients. A good number of the pharmacists believe that the effects have been moderately positive (45.6%) and moderately negative (32%). Majority (61.6%) of the community pharmacists now spend shorter time with patients during counseling. This is in contrast to the study carried out in Australia, where only a few pharmacists found the provision of clinical services and medication counseling challenging (Sum and Ow, 2020). The structural increase in the distance between pharmacists and patients negatively influences patient-pharmacist interaction (Koster *et al.*, 2020b). Some respondents have had to stop checking blood pressure and blood sugar level. This could also be due to physical distancing. Decrease in the quality of follow up evaluation has also been noticed. This could be due to the inadequate patient-pharmacist time, physical distancing and advice for elderly patients and ill to stay home. Social and physical distancing may compromise the quality of patient care and medication counseling provided in community pharmacists. However, to ensure the safety of patients and staff, the use of tele-pharmacy has been encouraged (Sum and Ow, 2020). Tele-pharmacy and use of online education tools have been promoted to facilitate communication between pharmacists and their patients (Liu *et al.*, 2020). However, only very few of the respondents were able to employ the use of tele-pharmacy and online pharmacy. The methods are difficult because many patients have limited digital skills as well as health literacy and therefore are at risk of drug related problems (Koster *et al.*, 2020a).

Also, the use of logistic procedures to deliver drugs to patients have been implemented. This is essential especially for high risk patients such as elderly patients and critically ill patients (Koster *et al.*, 2020b). Overall, many of the community pharmacists ensured the practice of the COVID-19 protocols recommended by the NCDC.

Majority of the respondents agreed that COVID-19 has affected the ready availability of medicines in their pharmacies. This could be as a result of limited importation of goods from other countries (mainly China and India) and the panic buying practice of customers in response to the pandemic (Uwizeyimana et al., 2021). Also the price increase from pharmaceutical wholesalers and patients buying unnecessary and excessive products have also contributed to the unavailability of some drugs (Hoti et al., 2020). The COVID-19 pharmaceutical goods were the most affected class of medicines including face masks, sanitizers and preventive or protective equipment (PPE). This is similar to a study conducted in Bangladesh, where over 95% of the stores recorded an increase in the purchase of PPE (Haque et al., 2020). Other medicines like antimalarials and antimicrobials were also affected. The antibiotics and immune boosters were short in supply in most pharmacies due to increased demand for them. This is similar to a study carried out in developing countries, where it was shown that there was an increase in utilization of antibiotics and multivitamins in Nigeria, Pakistan, Bangladesh, Ghana and Vietnam (Sefah et al., 2021). Antimalarials, principally hydroxychloroquine, were also short in supply in some pharmacies (12%). This is also similar to the study carried out in developing countries, where there was an increase in utilization of hydroxychloroquine across most African countries except Namibia (Sefah et al., 2021). This is as a result of its use as a prophylaxis or treatment of COVID-19 despite the controversies against its usefulness (WHO, 2020h).

Findings from this study shows that there were dramatic price changes on a few medicines, especially the immune boosters and antimalarial medicines. This is similar to the study conducted in Bangladesh where dramatic price changes were also noticed. This is as a result of the decrease in importation and increase in utilization during the pandemic (Haque et al., 2020). Increase in local production could help address the situation (EAC, 2020).

## CONCLUSION

The research findings reveal that the coronavirus disease 2019 (COVID-19) had considerable impact on the delivery of pharmaceutical care to patients and on the availability of drugs in community pharmacies in Lagos state. Although the lockdown was quite challenging, community pharmacy continued to provide services by implementing measures to reduce the spread of COVID-19. These measures caused a decrease in interaction between pharmacists and their patients. To improve delivery of patient care, pharmacists identified the importance of logistics services and tele-pharmacy in healthcare. Provision of drugs and other pharmaceutical products was challenging, but pharmacists were able to ensure steady delivery of drugs by ensuring bulk purchasing and always contacting suppliers.

## Data Availability

All data produced in the present work are contained in the manuscript

## Footnotes

*   This version of the manuscript has been revised to update the author list and the author affiliations.

*   Received November 2, 2024.
*   Revision received November 17, 2024.
*   Accepted November 17, 2024.


*   © 2024, Posted by Cold Spring Harbor Laboratory

This pre-print is available under a Creative Commons License (Attribution-NonCommercial-NoDerivs 4.0 International), CC BY-NC-ND 4.0, as described at [http://creativecommons.org/licenses/by-nc-nd/4.0/](http://creativecommons.org/licenses/by-nc-nd/4.0/)

## REFERENCES

1.  Alabi, M. (2021) COVID-19: Nigeria records first case of ‘most transmissible’ delta variant. Available from: [www.premiumtimesng.com](https://www.premiumtimesng.com) (Accessed August 4, 2021).
    
    

2.  Alexander, G. C. and Qato, D. M. (2020) Ensuring access to medications in the US during the COVID-19 pandemic. JAMA 2020; 324(1):31.
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=32271871&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F11%2F17%2F2024.11.02.24316307.atom) 

3.  Azeez, W. (2021) COVID-19: Nigeria logs 497 new infections in 18 states — but zero deaths. Available from: [https://www.thecablee.ng/covid-19-nigeria-logs-497-new-infections-in-18-states-but-zero-deaths/amp](https://www.thecablee.ng/covid-19-nigeria-logs-497-new-infections-in-18-states-but-zero-deaths/amp) (Accessed October 7, 2021).
    
    

4.  Bergman, S. J. (2021) COVID-19 treatment: investigational drugs and other therapies. Medscape, 4–19. Available from: [https://emedicine.medscape.com/article/2500116-overview](https://emedicine.medscape.com/article/2500116-overview) (Accessed September 21, 2021).
    
    

5.  Bluml, B. M., Watson, L. L., Skelton, J. B., Manolakis, P. G. and Brock, K. A. (2014) Improving outcomes for diverse populations disproportionately affected by diabetes: final results of Project IMPACT: Diabetes. Journal of American Pharmacists Association, 54(5), 477–485.
    
    

6.  Brodie, D. C. (1981) Pharmacy’s societal purpose. American Journal of Hospital Pharmacy 38(12), 1893–1896.
    
    [Abstract](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6NDoiYWpocCI7czo1OiJyZXNpZCI7czoxMDoiMzgvMTIvMTg5MyI7czo0OiJhdG9tIjtzOjUwOiIvbWVkcnhpdi9lYXJseS8yMDI0LzExLzE3LzIwMjQuMTEuMDIuMjQzMTYzMDcuYXRvbSI7fXM6ODoiZnJhZ21lbnQiO3M6MDoiIjt9) 

7.  Byambasuren, O., Cardona, M., Bell, K., Clark, J., McLaws, M. L. and Glasziou, P. (2020). Estimating the extent of asymptomatic COVID-19 and its potential for community transmission: Systematic review and meta-analysis. Official Journal of the Association of Medical Microbiology and Infectious Disease Canada, COVID-19.
    
    

8.  Campbell, J. (10 July 2012) This is Africa’s new biggest city: Lagos, Nigeria, population 21 million. Available from: [https://www.theatlantic.com/](https://www.theatlantic.com/) (Accessed June 26, 2021).
    
    

9.  Cennimo, D. J. (2021) Coronavirus Disease 2019 (COVID-19). Available from: [https://emedicine.medscape.com/article/2500114-overview](https://emedicine.medscape.com/article/2500114-overview) (Accessed May 21, 2021).
    
    

10. CDC (2020a) Centre for Disease Control. How COVID-19 spreads. Available from: [https://www.cdc.gov](https://www.cdc.gov) (Accessed August 2, 2021).
    
    

11. CDC (2020b) Centre for Disease Control. Guidance for pharmacies. Available from: [https://www.cdc.gov](https://www.cdc.gov) (Accessed August 2, 2021).
    
    

12. CDC (2020c) Centre for Disease Control. Symptoms of Coronavirus. Available at [https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html](https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html) (Accessed July 26, 2021).
    
    

13. CDC (2020d) Centre for Disease Control. 2019 novel coronavirus, Wuhan, China: interim healthcare infection prevention and control recommendations for patients under investigation for 2019 novel coronavirus. Available from: [https://www.cdc.gov/coronavirus/2019-ncov/infection-control.html](https://www.cdc.gov/coronavirus/2019-ncov/infection-control.html) (Accessed May 27, 2021).
    
    

14. Cherian, S., Potdar, V., Jadhav, S., Yadav, P., Gupta, N., Das, M., Das, S., Agarwal, A., Singh, S., Abraham, P., Panda, S., Mande, S., Swarup, R., Bhargava, B. and Bhushan, R. (2021) Convergent evolution of SARS-CoV-2 spike mutations, L452R, E484Q and P681R, in the second wave of COVID-19 in Maharashtra, India. Available from: doi:10.1101/2021.04.22.440932 (Accessed July 26, 2021).
    
    [Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6NzoiYmlvcnhpdiI7czo1OiJyZXNpZCI7czoxOToiMjAyMS4wNC4yMi40NDA5MzJ2MiI7czo0OiJhdG9tIjtzOjUwOiIvbWVkcnhpdi9lYXJseS8yMDI0LzExLzE3LzIwMjQuMTEuMDIuMjQzMTYzMDcuYXRvbSI7fXM6ODoiZnJhZ21lbnQiO3M6MDoiIjt9) 

15. Cipolle, R. J., Strand, L. M., Morley, P. C. and Frakes, M. J. (2004) The impact of pharmaceutical care practice on the practitioner and the patient in the ambulatory practice setting: twenty-five years of experience. Current Pharmaceutical Design, 10(31), 3987–4001.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.2174/1381612043382576&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=15579084&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F11%2F17%2F2024.11.02.24316307.atom) 

16. East African Community Secretariat. (2020) East African Community COVID-19 response plan. Available from: [https://www.eac.int/coronavirus](https://www.eac.int/coronavirus) (Accessed August 2, 2021).
    
    

17. Edara. V. V., Lai, L., Sahoo, M. K., Floyd, K., Sibai, M., Solis, D., Flowers, M. W., Hussaini, L., Ciric, C. R., Bechnack, S., Stephens, K., Mokhtari, E. B., Mudvari, P., Creanga, A., Pegu, A., Derrien-Colemyn, A., Henry, A. R., Gagne, M., Graham, B. S., Wrammert, J., Douek, D. C., Boritz, E., Pinsky, B. A. and Suthar, M. S. (2021) Infection and vaccine-induced neutralizing antibody responses to the SARS-CoV-2 B.1.617.1 variant. Available from: doi:10.1101/2021.05.09.443299 (Accessed June 26, 2021).
    
    [Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6NzoiYmlvcnhpdiI7czo1OiJyZXNpZCI7czoxOToiMjAyMS4wNS4wOS40NDMyOTl2MSI7czo0OiJhdG9tIjtzOjUwOiIvbWVkcnhpdi9lYXJseS8yMDI0LzExLzE3LzIwMjQuMTEuMDIuMjQzMTYzMDcuYXRvbSI7fXM6ODoiZnJhZ21lbnQiO3M6MDoiIjt9) 

18. Emanuel, E. J., Persad, G., Upshur, R., Thorne, B., Parker, M., Glickman, A., Zhang, C., Boyle, C., Smith, M. and Phillips, J. P. (2020) Fair allocation of scarce medical resources in the time of COVID-19. New England Journal of Medicine.
    
    

19. Esposito, S., Principi, N., Leung, C. C. and Migliori, G. B. (2020) Universal use of face masks for success against COVID-19: evidence and implications for prevention policies. European Respiratory Journal, 55(2001260).
    
    [Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6MzoiZXJqIjtzOjU6InJlc2lkIjtzOjEyOiI1NS82LzIwMDEyNjAiO3M6NDoiYXRvbSI7czo1MDoiL21lZHJ4aXYvZWFybHkvMjAyNC8xMS8xNy8yMDI0LjExLjAyLjI0MzE2MzA3LmF0b20iO31zOjg6ImZyYWdtZW50IjtzOjA6IiI7fQ==) 

20. Ewokor, C. (2021) Nigeria’s Covid-19 cases count crosses 100,000 mark. Available from: [https://www.bbc.com/](https://www.bbc.com/) (Accessed June 26, 2021)
    
    

21. FDA (2020) Food and Drug Administration. (2020) FDA approves first treatment for COVID-19. Available from: [https://www.fda.org](https://www.fda.org) (Accessed August 2, 2021).
    
    

22. Gallegos, A. (2020) WHO Declares Public Health Emergency for Novel Coronavirus. Available from: [https://www.medscape.com/viewarticle/924596](https://www.medscape.com/viewarticle/924596) (Accessed July 21, 2021).
    
    

23. Goode, J. R., Bennett, M. S. and Burns, A. L. (2019) A marathon, not a sprint: growth and evolution of community-based pharmacy residency education and training. Journal of the American College of Clinical Pharmacy, 2(4), 402–413.
    
    

24. Guanjian, L., Weiran, L., Xiaojin, H. and Yunxia, C. (2020) Asymptomatic and presymptomatic infectors: hidden sources of coronavirus disease 2019 (COVID-19). Clinical Infectious Diseases, 71(8), 2018.
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=32271372&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F11%2F17%2F2024.11.02.24316307.atom) 

25. Haque, M., Islam, S., Iqbal, S., Urmi, U. L., Kamal, Z. M., Rahman, A., Kamal, M., Haque, M., Jahan, I., Islam, Z., Hossain, M. M., Munzur-E-Murshid, Sefah, I., Kurdi, A. and Godman, B. (2020) Availability and price changes of potential medicines and equipment for the prevention and treatment of COVID-19 among pharmacy and drug stores in Bangladesh; findings and implications. Bangladesh Journal of Medical Science, 19, 36–50.
    
    

26. Hayden, J. C. and Parkin, R. (2020) The challenges of COVID-19 for community pharmacists and opportunities for the future. Available from: [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7276501/](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7276501/) (Accessed August 2, 2021).
    
    

27. Hedima, E. W., Adeyemi, M. S. and Ikunaiye, N. Y. (2020) Community pharmacists: on the frontline of health service against COVID-19 in LMICs. Available from: [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7162785/](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7162785/) (Accessed May 28, 2021).
    
    

28. Hepler, C. D. and Strand, L. M. (1990) Opportunities and responsibilities in pharmaceutical care. American Journal of Hospital Pharmacy, 47, 533–543.
    
    [Abstract](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6NDoiYWpocCI7czo1OiJyZXNpZCI7czo4OiI0Ny8zLzUzMyI7czo0OiJhdG9tIjtzOjUwOiIvbWVkcnhpdi9lYXJseS8yMDI0LzExLzE3LzIwMjQuMTEuMDIuMjQzMTYzMDcuYXRvbSI7fXM6ODoiZnJhZ21lbnQiO3M6MDoiIjt9) 

29. Hoti, K., Jakupi, A., Hetemi, D., Raka, D., Hughes, J. & Desselle, S. (2020) Provision of community pharmacy services during COVID-19 pandemic: a cross sectional study of community pharmacists’ experiences with preventive measures and sources of information. International Journal of Clinical Pharmacy, 42, 1197–1206.
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=32524513&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F11%2F17%2F2024.11.02.24316307.atom) 

30. Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., Cheng, Z., Yu, T., Xia, J., Wei, Y., Wu, W., Xie, X., Yin, W., Li, H., Liu, M., Xiao, Y., Gao, H., Guo, L., Xie, J., Wang, G., Jiang, R., Gao, Z., Jin, Q., Wang, J. and Cao, B. (2020) Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet, 395(10223), 497–506.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/S0140-6736(20)30183-5&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F11%2F17%2F2024.11.02.24316307.atom) 

31. Ibrahim, R. L., Ajide, K. B. and Julius, O. O. (2020) Easing of lockdown measures in Nigeria: Implications for the healthcare system. Available from: [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7490626](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7490626) (Accessed June 2, 2021).
    
    

32. Joda, A. E., Olugbake, O. A., Oyetunde, O. O., Awofisayo, O., Ibrahim, M., Williams, F. E., Ayeni, F. A., Mosanya, A. U. and Ologunagba, M. O. (2020) Pharmacists’ Perception of their Roles and Involvement in Coronavirus Disease 2019 (COVID-19). Journal of Basic and Social Pharmacy Research.
    
    

33. Koster, E. S., Philber, D. and Bouvy, M. L. (2020a) Health literacy among pharmacy visitors in the Netherlands. Pharmacoepidemiol Drug Saf, 24(7), 716–721.
    
    

34. Koster, E. S., Philber, D. and Bouvy, M. L. (2020b) Impact of the COVID-19 epidemic on the provision of pharmaceutical care in community pharmacies. Available from: [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7330552](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7330552) (Accessed August 2, 2021).
    
    

35. Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman A. S., Reich, N. S., and Lessler, J. (2020) The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Available from: doi:10.7326/M20-0504 (Accessed June 20, 2020).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.7326/M20-0504&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=32150748&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F11%2F17%2F2024.11.02.24316307.atom) 

36. Liu, S., Luo, P. and Tang, M. (2015) Providing pharmacy services during the coronavirus pandemic. International Clinical Pharmacy, 28, 1–6.
    
    

37. Mbah, F. (April 14, 2020) Nigeria announces lockdown of major cities to curb coronavirus. Available from: [https://www.aljazeera.com](https://www.aljazeera.com) (Accessed August 2, 2021).
    
    

38. Mikeal, R. L., Lazarus, H. L., Vinson, M. C. and Brown, T. R. (1975) Quality of pharmaceutical care in hospitals. American Journal of Hospital Pharmacy, 32(6), 567–574.
    
    [Abstract](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6NDoiYWpocCI7czo1OiJyZXNpZCI7czo4OiIzMi82LzU2NyI7czo0OiJhdG9tIjtzOjUwOiIvbWVkcnhpdi9lYXJseS8yMDI0LzExLzE3LzIwMjQuMTEuMDIuMjQzMTYzMDcuYXRvbSI7fXM6ODoiZnJhZ21lbnQiO3M6MDoiIjt9) 

39. NCDC (2020a) National Centre for Disease Control. First case of coronavirus disease confirmed in Nigeria. Available from: [https://ncdc.gov.ng/news/227/first-case-of-corona-virus-disease-confirmed-in-Nigeria](https://ncdc.gov.ng/news/227/first-case-of-corona-virus-disease-confirmed-in-Nigeria) (Accessed 21 May, 2021).
    
    

40. NCDC (2020b) National Centre for Disease Control. Guidelines – NCDC coronavirus COVID-19 microsite. Available from: [https://www.covid19.ncdc.gov.ng](https://www.covid19.ncdc.gov.ng) (Accessed October 4, 2021).
    
    

41. NCDC (2020c) National Centre for Disease Control. NCDC on twitter: 1,145 new cases of #COVID-19 Nigeria. Available from: [https://twitter.com](https://twitter.com) (Accessed September 17, 2021).
    
    

42. NCDC (2020d) National Centre for Disease Control. COVID-19 Outbreak in Nigeria situation report. Available from: https://ncdc.gov.ng/diseases/sitreps/?cat=14&name=An%20update%20of%20COVID-19%20outbreak%20in%20Nigeria. (Accessed 21 May, 2021).
    
    

43. NCDC (2020e) National Centre for Disease Control. NCDC twitter status. #COVID-19 Myths and Facts. Available from: [https://twitter.com/ncdcgov/status/129](https://twitter.com/ncdcgov/status/129) 5787664596258825 (Accessed September 17, 2021).
    
    

44. NCDC (2021a) National Centre for Disease Control. COVID-19 situation report 12. Available from: [https://www.covid19.ncdc.gov.ng](https://www.covid19.ncdc.gov.ng) (Accessed October 4, 2021).
    
    

45. NCDC (2021b) National Centre for Disease Control. COVID-19 situation report 25. Available from: [https://www.covid19.ncdc.gov.ng](https://www.covid19.ncdc.gov.ng) (Accessed October 4, 2021).
    
    

46. NCDC (2021c) National Centre for Disease Control. COVID-19 situation report 38. Available from: [https://www.covid19.ncdc.gov.ng](https://www.covid19.ncdc.gov.ng) (Accessed October 4, 2021).
    
    

47. Nwosu, A. (2021) COVID-19: Nigeria records more deaths, over 626 fresh cases in 9 states, FCT. Available from: [https://www.google.com/amp/s/dailypost.ng/2021/09/01/covid-19-nigeria-records-more-deaths-over-626-fresh-cases-in-9-states-fct/](https://www.google.com/amp/s/dailypost.ng/2021/09/01/covid-19-nigeria-records-more-deaths-over-626-fresh-cases-in-9-states-fct/) (Accessed October 7, 2021).
    
    

48. Oladipo, E. K., Ajayi, A. F., Odeyemi, A. N., Akindiya, O. E., Adebayo, E. T., Oguntomi, A. S., Oyewole, M. P., Jimah, E. M., Oladipo, A. A., Ariyo, O. E., Oladipo, B. B. and Oloke, J. K. (2020) Laboratory diagnosis of COVID-19 in Africa: availability, challenges and implications. Drug Discovery and therapeutics, 14(4): 153–160.
    
    

49. Omilana T., (2020). Buhari extends phase two of COVID-19 lockdown by four weeks. Available from: [https://guardian.ng/news/buhari-extends-phase-two-of-covid-19-lockdown-by-four-weeks/](https://guardian.ng/news/buhari-extends-phase-two-of-covid-19-lockdown-by-four-weeks/) (Accessed May 21, 2021).
    
    

50. Ong, S. W., Tan, Y. K., Chia, P. Y., Lee, T. H., Ng, O. T., Wong, M. S. and Marimuthu, K. (2020) Air, surface environmental, and personal protective equipment contamination by severe acute respiratory syndrome coronavirus (SARS-CoV-2) from a symptomatic patient. JAMA, 323(16), 1610–1612.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1001/jama.2020.3227&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=32129805&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F11%2F17%2F2024.11.02.24316307.atom) 

51. Onuah, F. (2020). Nigeria warned of possible new COVID-19 wave, authorities eye vaccine in early 2021. Available from: [https://www.reuters.com/business/healthcare-pharmaceuticals/nigeria-warned-possible-new-covid-19-wave-authorities-eye-vaccine-early-2021-2020-12-11/](https://www.reuters.com/business/healthcare-pharmaceuticals/nigeria-warned-possible-new-covid-19-wave-authorities-eye-vaccine-early-2021-2020-12-11/) (Accessed September 17, 2021).
    
    

52. Oran, D. P. and Topol, E. J. (2020) Prevalence of asymptomatic SARS-CoV-2 infection: a narrative review. Available from: doi:10.7326/M20-3012 (Accessed May 24, 2021).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.7326/M20-3012&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=32296168&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F11%2F17%2F2024.11.02.24316307.atom) 

53. Owoseye, A. (2020) Updated coronavirus: second case confirmed in Nigeria. Available from: [www.premiumtimesng.com](https://www.premiumtimesng.com) (Accessed August 4, 2021).
    
    

54. Oyeyemi, T. (2020) Remarks by the chairman, PTF on COVID-19 at the national briefing of Monday, June 1, 2020. Available from: [https://guardian.ng/](https://guardian.ng/) (Accessed October 4, 2021).
    
    

55. Ozma, M. A., Maroufi, P., Khodadadi, E., Köse, S., Esposito, I., Ganbarov, K., Dao, S., Esposito, S., Dal, T., Zeinalzadeh, E. and Kafil, H. S. (2020) Clinical manifestation, diagnosis, prevention and control of SARS-CoV-2 (COVID-19) during the outbreak period. Le Infezioni in Medicina, 28(2), 153–165.
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=32275257&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F11%2F17%2F2024.11.02.24316307.atom) 

56. Patient Safety Network (29th June, 2020) Health care delivery and pharmacists during the COVID-19 pandemic. Available from: [https://psnet.ahrq.gov/perspective/health-care-delivery-and-pharmacists-during-covid-19-pandemic](https://psnet.ahrq.gov/perspective/health-care-delivery-and-pharmacists-during-covid-19-pandemic) (Accessed September 21, 2021).
    
    

57. PSN (2019) ACPN in brief. Available from: [https://www.lagospsn.com/](https://www.lagospsn.com/) (Accessed June 26, 2021).
    
    

58. Rabin, R. C. (2020) Lost Sense of Smell May Be Peculiar Clue to Coronavirus Infection. Available from: [https://www.nytimes.com/2020/03/22/health/coronavirus-symptoms-smell-taste.html](https://www.nytimes.com/2020/03/22/health/coronavirus-symptoms-smell-taste.html) (Accessed May 24, 2021).
    
    

59. Sefah, I. A., Ogunleye, O. O., Essah, D. O., Opanga, S. A., Butt, N., Wamaitha, A., Guantai, A. N., Chikowe, I., Khuluza, F., Kibuule, D., Nambahu, L., Abubakar, A. R., Sani, I. H., Saleem, Z., Kalungia, A. C., Thi Phuong, T. N., Haque, M., Islam, S., Kumar, S., Sneddon, J., Wamboga, J., Wale, J., Miljkovic, N., Kurdi, A., Martin, A. P., and Godman, B. (2021) Rapid assessment of the potential paucity and price increases for suggested medicines and protection equipment for COVID-19 across developing countries with a particular focus on Africa and the implications. Pharmacol, 11(588106).
    
    

60. Spinato, G., Fabbris, C., Polesel, J., Cazzador, D., Borsetto, D., Hopkins, C. and Bosco-lo-Rizzo, P. (2020) Alterations in Smell or Taste in Mildly Symptomatic Outpatients With SARS-CoV-2 Infection. JAMA, 323(20), 2089–2090.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1001/jama.2020.6771&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=32320008&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F11%2F17%2F2024.11.02.24316307.atom) 

61. Sum, Z. Z. and Ow, C. J. (2020) Community pharmacy response to infection control during COVID-19: a cross-sectional survey. Research in Social and Administrative Pharmacy. Available from: doi:10.1016/j.sapharm.2020.06.014 (Accessed August 2, 2021).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.sapharm.2020.06.014&link_type=DOI) 

62. The Nation Newspaper (2020) COVID-19: NCDC to follow up over 6000 contacts to curb spread of virus. Available from: [www.thenationonlineng.net](https://www.thenationonlineng.net) (Accessed October 4, 2021).
    
    

63. UNICEF Nigeria (2 March, 2021) COVID-19 vaccines shipped by COVAX arrive in Nigeria. Available from: [https://www.unicef.org/nigeria/press-releases/covid-19-vaccines-shipped-covax-arrive-nigeria](https://www.unicef.org/nigeria/press-releases/covid-19-vaccines-shipped-covax-arrive-nigeria) (Accessed October 4, 2021).
    
    

64. Uwizeyimana, T., Hashim, H. T., Kabakambira, J. D., Mujyarugamba, J. C., Dushime, J., Ntacyabukura, B., Ndayizeye, R., Adebisi, Y. A. and Lucero-Prisco, D.E. (2021) Drug suppy situation in Rwanda during COVID-19: issues, efforts and challenges. Journal of Pharmaceutical Policy and Practice 14(12).
    
    

65. Visscher, B. B., Steunenberg, B., Heerdink, E. R. and Rademaker, J. (2020) Medication self-management support for people with diabetes and low health literacy: a needs assessment. PloS One, 15(4).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1371/journal.pone.0232452&link_type=DOI) 

66. WHO (1994) World Health Organization. The role of the pharmacist in the health care system. Available from: apps.who.int (Accessed August 2, 2021).
    
    

67. WHO (2014) World Health Organization. Infection prevention and control of epidemic-and pandemic-prone acute respiratory infections in health care. Available from: [https://apps.who.int/iris/bitstream/handle/10665/sequence=1](https://apps.who.int/iris/bitstream/handle/10665/sequence=1) (Accessed August 2, 2021).
    
    

68. WHO (2019) World Health Organization. Novel coronavirus (2019-nCoV) situation report-1. Available from: [https://www.who.int](https://www.who.int) (Accessed August 2, 2021).
    
    

69. WHO (2020a) World Health Organization. Coronavirus disease (COVID-19). Available from: [https://www.who.int/health-topics/coronavirus#tab=tab1](https://www.who.int/health-topics/coronavirus#tab=tab1) (Accessed August 2, 2021).
    
    

70. WHO (2020b) World Health Organization. COVID-19 transmission and protective measures. Available from: [https://www.who.int/westernpacific/emergencies/covid-19/information/transmission-protective-measures](https://www.who.int/westernpacific/emergencies/covid-19/information/transmission-protective-measures) (Accessed October 4, 2021).
    
    

71. WHO (2020c) World Health Organization. COVID-19 weekly epidemiological update, 13. Available from: [https://www.who.int](https://www.who.int) (Accessed August 2, 2021).
    
    

72. WHO (2020d) World Health Organization. Coronavirus disease (COVID-19): how is it transmitted? Available from: [https://www.who.int](https://www.who.int) (Accessed August 2, 2021).
    
    

73. WHO (2020e) World Health Organization. Introduction to COVID-19: methods for detection, prevention, response and control. Available from: [https://www.openwho.org](https://www.openwho.org) (Accessed August 2, 2021).
    
    

74. WHO (2020f) World Health Organization. WHO Director-General’s opening remarks at the media briefing on COVID-19. Available from: [https://www.who.int](https://www.who.int) (Accessed August 2, 2021).
    
    

75. WHO (2020g) World Health Organization. Mode of transmission of virus causing COVID-19: implications for IPC precaution recommendations. Available from: [https://www.who.int](https://www.who.int) (Accessed August 2, 2021).
    
    

76. WHO (2020h) World Health Organization. Coronavirus disease (COVID-19) advice for the public – Myth-busters. Available at: [https://www.who.int/emergencies/diseases/novel-coronavirus-2019/advice-for-public/myth-busters?gclid=CjwKCAjwnK36BRBVEiwAsMT8WGdkpvdtJYmlZ-keQ1nARYA2D1\_BB1FpJkRvKBzchfuEtJjr7cbFRoC3nIQAvD_BwE](https://www.who.int/emergencies/diseases/novel-coronavirus-2019/advice-for-public/myth-busters?gclid=CjwKCAjwnK36BRBVEiwAsMT8WGdkpvdtJYmlZ-keQ1nARYA2D1_BB1FpJkRvKBzchfuEtJjr7cbFRoC3nIQAvD_BwE) (Accessed September 30, 2021).
    
    

77. Wiedenmayer, K., Summers, R. S., Mackie, C. A., Gous, A. G., Everard, M. and Tromp, D. (2006). Developing pharmacy practice: a focus on patient care. Handbook Geneva: World Health Organization, International Pharmaceutical Federation, 3-18.
    
    

78. Williamson, E. J., Walker, A. J., Bhaskaran, K., Bacon, S., Bates, C., Morton, C. E., Curtis, H. J., Mehrkar, A., Evans, D., Inglesby, P., Cockburn, J., McDonald, H. J., MacKenna, B., Tomlinson, L., Douglas, I. J., Rentsch, C. T., Mathur, R., Wong, A. Y., Grieve, R., Harrison, D., Forbes, H., Schultze, A., Croker, R., Parry, J., Hester, F., Harper, S., Perera, R., Evans, S. J., Smeeth, L. and Goldacre, B. (2020) Factors associated with COVID-19-related death using OpenSAFELY. Nature, 584, 430–436.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1038/s41586-020-2521-4&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=32640463&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F11%2F17%2F2024.11.02.24316307.atom) 

79. Wu, Z. and McGoogan, J. M. (2020) Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) Outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention.